This one is in the edition because it behaves exactly like the financial risks we spend our days on: everybody carries some, nobody knows their number, and the instinct is to avoid finding out. This week that number got measurable — you can now test your own blood for plastic.
We inhale and ingest microplastics from nearly everything, some of it accumulates, and the evidence that it matters is growing while the measurement is only starting. A consumer test will now read your blood and saliva.
That is Risk 08 on our own map wearing a lab coat. The behavior that makes someone avoid a blood test is the same behavior that makes them avoid opening a statement in a bad quarter.
Here is the part worth saying plainly for the book. This is not a position, it is a discipline dressed up as a health story, and the discipline travels: measure the uncomfortable number before it compounds out of sight. A portfolio review is the financial version of the blood panel — you look at the fee drag, the concentration, the actual cushion, precisely because the instinct is to assume them away. The clients who let us measure early are the ones who never get surprised by what was accumulating quietly the whole time.
No trade, and no pretending otherwise. This is here as a discipline, not a position: the cost of measuring something unpleasant is almost always lower than the cost of assuming it away. We apply that to a portfolio review the same way a doctor applies it to a panel — look first, decide second.